Search

Your search keyword '"Harrington, Susan M"' showing total 216 results
Start Over Author "Harrington, Susan M" Publication Year Range Last 50 years
216 results on '"Harrington, Susan M"'

3. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Author

Hieken, Tina J., primary, Nelson, Garth D., additional, Flotte, Thomas J., additional, Grewal, Eric P., additional, Chen, Jun, additional, McWilliams, Robert R., additional, Kottschade, Lisa A., additional, Yang, Lu, additional, Domingo-Musibay, Evidio, additional, Dronca, Roxana S., additional, Yan, Yiyi, additional, Markovic, Svetomir N., additional, Dimou, Anastasios, additional, Montane, Heather N., additional, Erskine, Courtney L., additional, Piltin, Mara A., additional, Price, Daniel L., additional, Khariwala, Samir S., additional, Hui, Jane, additional, Strand, Carrie A., additional, Harrington, Susan M., additional, Suman, Vera J., additional, Dong, Haidong, additional, and Block, Matthew S., additional

Published
2024
Full Text
View/download PDF

4. Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2024
Full Text
View/download PDF

7. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression

Author

Tang, Haidong, Liang, Yong, Anders, Robert A., Taube, Janis M., Qiu, Xiangyan, Mulgaonkar, Aditi, Liu, Xin, Harrington, Susan M., Guo, Jingya, Xin, Yangchun, Xiong, Yahong, Nham, Kien, Silvers, William, Hao, Guiyang, Sun, Xiankai, Chen, Mingyi, Hannan, Raquibul, Qiao, Jian, Dong, Haidong, Peng, Hua, and Fu, Yang-Xin

Subjects
Apoptosis -- Health aspects, Cancer regression -- Physiological aspects, Ligands (Biochemistry) -- Health aspects, Health care industry
Abstract

Programmed death-ligand 1 (PD-L1) expression on tumor cells is essential for T cell impairment, and PD-L1 blockade therapy has shown unprecedented durable responses in several clinical studies. Although higher expression of PD-L1 on tumor cells is associated with a better immune response after Ab blockade, some PD-L1- negative patients also respond to this therapy. In the current study, we explored whether PD-L1 on tumor or host cells was essential for anti-PD-L1-mediated therapy in 2 different murine tumor models. Using real-time imaging in whole tumor tissues, we found that anti-PD-L1 Ab accumulates in tumor tissues, regardless of the status of PD-L1 expression on tumor cells. We further observed that, while PD-L1 on tumor cells was largely dispensable for the response to checkpoint blockade, PD-L1 in host myeloid cells was essential for this response. Additionally, PD-L1 signaling in defined antigen-presenting cells (APCs) negatively regulated and inhibited T cell activation. PD-L1 blockade inside tumors was not sufficient to mediate regression, as limiting T cell trafficking reduced the efficacy of the blockade. Together, these findings demonstrate that PD-L1 expressed in APCs, rather than on tumor cells, plays an essential role in checkpoint blockade therapy, providing an insight into the mechanisms of this therapy., Introduction The programmed death-1 receptor/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway plays an important role in tumor evasion of host immune responses (1). Recent clinical trials with PD-1/PD-L1 blockade therapy have [...]

Published
2018
Full Text
View/download PDF

8. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma

Author

An, Zesheng, primary, Hsu, Michelle A., additional, Gicobi, Joanina K., additional, Xu, Tianxiao, additional, Harrington, Susan M., additional, Zhang, Henan, additional, Pavelko, Kevin D., additional, Hirdler, Jacob B., additional, Lohse, Christine M., additional, Nabavizadeh, Reza, additional, Pessoa, Rodrigo R., additional, Sharma, Vidit, additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2023
Full Text
View/download PDF

9. Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Data from NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, primary, Li, Ying, primary, Zhang, Henan, primary, Gicobi, Joanina K., primary, Hirdler, Jacob B., primary, Liu, Xin, primary, Ham, Hyoungjun, primary, Peterson Martinez, Kodi E., primary, Lucien, Fabrice, primary, Lavoie, Roxane R., primary, Li, Hu, primary, Correia, Cristina, primary, Monie, Dileep D., primary, An, Zesheng, primary, Harrington, Susan M., primary, Wu, Xiaosheng, primary, Guo, Ruifeng, primary, Dronca, Roxana S., primary, Mansfield, Aaron S., primary, Yan, Yiyi, primary, Markovic, Svetomir N., primary, Park, Sean S., primary, Sun, Jie, primary, Qin, Hong, primary, Liu, Minetta C., primary, Vasmatzis, George, primary, Billadeau, Daniel D., primary, and Dong, Haidong, primary

Published
2023
Full Text
View/download PDF

14. Data from PD-1 Restrains Radiotherapy-Induced Abscopal Effect

Author

Park, Sean S., primary, Dong, Haidong, primary, Liu, Xin, primary, Harrington, Susan M., primary, Krco, Christopher J., primary, Grams, Michael P., primary, Mansfield, Aaron S., primary, Furutani, Keith M., primary, Olivier, Kenneth R., primary, and Kwon, Eugene D., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

18. Data from Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, primary, Foster, Nathan R., primary, Hartley, Christopher, primary, Mounajjed, Taofic, primary, Salomao, Marcela A., primary, Fruth, Briant F., primary, Beamer, Staci E., primary, Kim, Yohan, primary, Harrington, Susan M., primary, Pitot, Henry C., primary, Sanhueza, Cristobal T., primary, Feng, Yening, primary, Herrmann, Joerg, primary, McWilliams, Robert R., primary, Lucien, Fabrice, primary, Huang, Bing Q., primary, Ma, Wen Wee, primary, Bekaii-Saab, Tanios S., primary, Dong, Haidong, primary, Wigle, Dennis, primary, Ahn, Daniel H., primary, Hallemeier, Chris L., primary, Blackmon, Shanda, primary, and Yoon, Harry H., primary

Published
2023
Full Text
View/download PDF

19. Legend for Supplemental Figure 2legend from Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma

Author

Gustafson, Michael P., primary, Lin, Yi, primary, Bleeker, Jonathan S., primary, Warad, Deepti, primary, Tollefson, Matthew K., primary, Crispen, Paul L., primary, Bulur, Peggy A., primary, Harrington, Susan M., primary, Laborde, Rebecca R., primary, Gastineau, Dennis A., primary, Leibovich, Bradley C., primary, Cheville, John C., primary, Kwon, Eugene D., primary, and Dietz, Allan B., primary

Published
2023
Full Text
View/download PDF

21. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels

Author

Sideras, Kostandinos, de Man, Robert A., Harrington, Susan M., Polak, Wojciech G., Zhou, Guoying, Schutz, Hannah M., Pedroza-Gonzalez, Alexander, Biermann, Katharina, Mancham, Shanta, Hansen, Bettina E., Bart Takkenberg, R., van Vuuren, Anneke J., Pan, Qiuwei, Ijzermans, Jan N. M., Sleijfer, Stefan, Sprengers, Dave, Dong, Haidong, Kwekkeboom, Jaap, and Bruno, Marco J.

Published
2019
Full Text
View/download PDF

22. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors

Author

Barham, Whitney, primary, Hsu, Michelle, additional, Liu, Xin, additional, Harrington, Susan M., additional, Hirdler, Jacob B., additional, Gicobi, Joanina K., additional, Zhu, Xingxing, additional, Zeng, Hu, additional, Pavelko, Kevin D., additional, Yan, Yiyi, additional, Mansfield, Aaron S., additional, and Dong, Haidong, additional

Published
2023
Full Text
View/download PDF

23. Discovery of a novel monoclonal PD-L1 antibody H1A that promotes T-cell mediated tumor killing activity in renal cell carcinoma

Author

An, Zesheng, primary, Hsu, Michelle A., additional, Gicobi, Joanina K., additional, Xu, Tianxiao, additional, Harrington, Susan M., additional, Zhang, Henan, additional, Pavelko, Kevin D., additional, Hirdler, Jacob B., additional, Lohse, Christine M., additional, Nabavizadeh, Reza, additional, Pessoa, Rodriguo R., additional, Sharma, Vidit, additional, Thompson, R. Houston, additional, Leibovich, Bradley C., additional, Dong, Haidong, additional, and Lucien, Fabrice, additional

Published
2022
Full Text
View/download PDF

25. A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitors

Author

Barham, Whitney, primary, Hsu, Michelle, additional, Liu, Xin, additional, Harrington, Susan M., additional, Hirdler, Jacob B., additional, Gicobi, Joanina K., additional, Zhu, XingXing, additional, Zeng, Hu, additional, Pavelko, Kevin D., additional, Yan, Yiyi, additional, Mansfield, Aaron S., additional, and Dong, Haidong, additional

Published
2022
Full Text
View/download PDF

29. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Author

Zhu, Mojun, primary, Chen, Chunhua, additional, Foster, Nathan R., additional, Hartley, Christopher, additional, Mounajjed, Taofic, additional, Salomao, Marcela A., additional, Fruth, Briant F., additional, Beamer, Staci E., additional, Kim, Yohan, additional, Harrington, Susan M., additional, Pitot, Henry C., additional, Sanhueza, Cristobal T., additional, Feng, Yening, additional, Herrmann, Joerg, additional, McWilliams, Robert R., additional, Lucien, Fabrice, additional, Huang, Bing Q., additional, Ma, Wen Wee, additional, Bekaii-Saab, Tanios S., additional, Dong, Haidong, additional, Wigle, Dennis, additional, Ahn, Daniel H., additional, Hallemeier, Chris L., additional, Blackmon, Shanda, additional, and Yoon, Harry H., additional

Published
2022
Full Text
View/download PDF

30. NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

Author

Wen, Ti, primary, Barham, Whitney, additional, Li, Ying, additional, Zhang, Henan, additional, Gicobi, Joanina K., additional, Hirdler, Jacob B., additional, Liu, Xin, additional, Ham, Hyoungjun, additional, Peterson Martinez, Kodi E., additional, Lucien, Fabrice, additional, Lavoie, Roxane R., additional, Li, Hu, additional, Correia, Cristina, additional, Monie, Dileep D., additional, An, Zesheng, additional, Harrington, Susan M., additional, Wu, Xiaosheng, additional, Guo, Ruifeng, additional, Dronca, Roxana S., additional, Mansfield, Aaron S., additional, Yan, Yiyi, additional, Markovic, Svetomir N., additional, Park, Sean S., additional, Sun, Jie, additional, Qin, Hong, additional, Liu, Minetta C., additional, Vasmatzis, George, additional, Billadeau, Daniel D., additional, and Dong, Haidong, additional

Published
2021
Full Text
View/download PDF

37. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles

Author

Orme, Jacob J, primary, Enninga, Elizabeth Ann L, additional, Lucien-Matteoni, Fabrice, additional, Dale, Heather, additional, Burgstaler, Edwin, additional, Harrington, Susan M, additional, Ball, Matthew K, additional, Mansfield, Aaron S, additional, Park, Sean S, additional, Block, Mathew S, additional, Markovic, Svetomir N, additional, Yan, Yiyi, additional, Dong, Haidong, additional, Dronca, Roxana S, additional, and Winters, Jeffrey L, additional

Published
2020
Full Text
View/download PDF

39. Acid-fast Smear and Histopathology Results Provide Guidance for the Appropriate Use of Broad-Range Polymerase Chain Reaction and Sequencing for Mycobacteria

Author

Miller, Kennon, Harrington, Susan M., and Procop, Gary W.

Subjects
Nucleotide sequencing -- Usage, Air bases -- Usage, Histochemistry -- Usage, DNA sequencing -- Usage, Tuberculosis -- Usage, Bacterial infections -- Usage, Polymerase chain reaction -- Usage, Health
Abstract

Context.--New molecular diagnostic tests are attractive because of the potential they hold for improving diagnostics in microbiology. The value of these tests, which is often assumed, should be investigated to determine the best use of these potentially powerful tools. Objective.--To investigate the usefulness of broad-range polymerase chain reaction (PCR), followed by sequencing, in mycobacterial infections. Design.--We reviewed the test performance of acid-fast bacilli (AFB) PCR and traditional diagnostic methods (histopathology, AFB smear, and culture). We assessed the diagnostic effect and cost of the unrestricted ordering of broad-range PCR for the detection and identification of mycobacteria in clinical specimens. Results.--The AFB PCR was less sensitive than culture and histopathology and was less specific than culture, AFB smear, and histopathology. During 18 months, $93 063 was spent on 183 patient specimens for broad-range PCR and DNA sequencing for mycobacteria to confirm one culture-proven Mycobacterium tuberculosis infection that was also known to be positive by AFB smear and histopathology. In this cohort, there was a false-negative AFB PCR for M tuberculosis and a false-positive AFB PCR for Mycobacterium lentiflavum. Conclusion.--Testing of AFB smear-negative specimens from patients without an inflammatory response supportive of a mycobacterial infection is costly and has not been proven to improve patient care. Traditional diagnostics (histopathology, AFB smear, and culture) should remain the primary methods for the detection of mycobacteria in clinical specimens. (Arch Pathol Lab Med. 2015; 139:1020-1023; doi: 10.5858/arpa.2013-0705-OA), Selection of the optimum tests for a specimen becomes more challenging as newer testing methods become increasingly available for the detection of microorganisms. Polymerase chain reaction (PCR)-based methods for microorganism [...]

Published
2015
Full Text
View/download PDF

42. A Comparison of Five SARS-CoV-2 Molecular Assays With Clinical Correlations.

Author

Procop, Gary W, Brock, Jay E, Reineks, Edmunds Z, Shrestha, Nabin K, Demkowicz, Ryan, Cook, Eleanor, Ababneh, Emad, and Harrington, Susan M

Subjects
SARS-CoV-2, COVID-19, NUCLEIC acid amplification techniques
Abstract

Objectives: Comparative assessments of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) molecular assays that have been operationalized through the US Food and Drug Administration's Emergency Use Authorization process are warranted to assess real-world performance. Characteristics such as sensitivity, specificity, and false-negative rate are important to inform clinical use.Methods: We compared five SARS-CoV-2 assays using nasopharyngeal and nasal swab specimens submitted in transport media; we enriched this cohort for positive specimens, since we were particularly interested in the sensitivity and false-negative rate. Performance of each test was compared with a composite standard.Results: The sensitivities and false-negative rates of the 239 specimens that met inclusion criteria were, respectively, as follows: Centers for Disease Control and Prevention 2019 nCoV Real-Time RT-PCR Diagnostic Panel, 100% and 0%; TIB MOLBIOL/Roche z 480 Assay, 96.5% and 3.5%; Xpert Xpress SARS-CoV-2 (Cepheid), 97.6% and 2.4%; Simplexa COVID-19 Direct Kit (DiaSorin), 88.1% and 11.9%; and ID Now COVID-19 (Abbott), 83.3% and 16.7%.Conclusions: The assays that included a nucleic acid extraction followed by reverse transcription polymerase chain reaction were more sensitive than assays that lacked a full extraction. Most false negatives were seen in patients with low viral loads, as extrapolated from crossing threshold values. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. B7-H1(PD-L1) confers chemoresistance through ERK and p38 MAPK pathway in tumor cells

Author

Wu, Xiaosheng, primary, Li, Yanli, additional, Liu, Xin, additional, Cao, Siyu, additional, Harrington, Susan M., additional, Chen, Chunhua, additional, Mansfiled, Aaron S., additional, Dronca, Roxana S., additional, Park, Sean S., additional, Yan, Yiyi, additional, Kwon, Eugene D., additional, Wang, Liewei, additional, Ling, Kun, additional, and Dong, Haidong, additional

Published
2018
Full Text
View/download PDF

45. CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Author

Yan, Yiyi, primary, Cao, Siyu, additional, Liu, Xin, additional, Harrington, Susan M., additional, Bindeman, Wendy E., additional, Adjei, Alex A., additional, Jang, Jin Sung, additional, Jen, Jin, additional, Li, Ying, additional, Chanana, Pritha, additional, Mansfield, Aaron S., additional, Park, Sean S., additional, Markovic, Svetomir N., additional, Dronca, Roxana S., additional, and Dong, Haidong, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results